CTI BioPharma Corp. (NASDAQ:CTIC)’s traded shares stood at 1,181,040 during the last session, with the company’s beta value hitting 0.89. At the close of trading, the stock’s price was $3.74, to imply an increase of 6.09% or $0.21 in intraday trading. The CTIC share’s 52-week high remains $3.88, putting it -3.74% down since that peak but still an impressive +83.42% since price per share fell to its 52-week low of $0.62. The company has a valuation of $276.2 Million, with an average of 681.73 Million shares in intraday trading volume over the past 10 days and average of 3.36 Million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for CTI BioPharma Corp. (CTIC), translating to a mean rating of 2. Of 4 analyst(s) looking at the stock, none analyst(s) give CTIC a Sell rating. None of those analysts rate the stock as Overweight while no one advise Hold as 4 recommend it as a Buy. None analyst(s) have given it an Underweight rating. Estimates put the company’s earnings per share at -$0.16.
CTI BioPharma Corp. (NASDAQ:CTIC) trade information
After registering a 6.09% upside on the day, CTI BioPharma Corp. (CTIC) has traded green over the past five days. The stock hit a weekly high of $3.88-3 this Friday, Nov 20, jumping 3.61% in its intraday price action. The 5-day price performance for the stock is 9.04%, and 15.43% over 30 days. With these gigs, the year-to-date price performance is 136.71%. Short interest in CTI BioPharma Corp. (NASDAQ:CTIC) saw shorts transact 577.56 Million shares and set a 171.89 days time to cover.
Analysts on Wall Street suggest a consensus price target of $6.25, implying an increase of 67.11% to the stock’s current value. The extremes give us $4 and $8 for target low and target high price respectively. As such, CTIC is trading +113.9% off suggested target high and 6.95% from its likely low.
CTI BioPharma Corp. (CTIC) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 36.1% for the past 5-year period. While 2020 is set for a -31.7% return in earnings, projections for the next 5 years are at 0% annually.
CTI BioPharma Corp. (NASDAQ:CTIC)’s Major holders
CTI BioPharma Corp. insiders hold 0.25% of total outstanding shares, with institutional holders owning 56.87% of the shares at 57.02% float percentage. In total, 49 institutions holds shares in the company, led by Orbimed Advisors LLC. As of Sep 29 this year, the company held over 9.52 Million shares (or 12.91% of shares), all amounting to roughly $20.47 Million.
The next major institution holding the largest number of shares is NEA Management Company, LLC with 7.14 Million shares, or about 9.68% of shares outstanding. As of the market price on 44103, these shares were worth $15.35 Million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the CTI BioPharma Corp. (CTIC) shares. Going by data provided on 44011, Vanguard Total Stock Market Index Fund holds roughly 1,356,188 shares. This is just over 1.84% of the total shares, with a market valuation of $1.57 Million. Data from the same date shows that the other fund manager holds a little less at 679.12 Thousand, or 0.92% of the shares, all valued at about $787.78 Thousand.